KLRK1 and acute myeloid leukemia: After establishing best agent, dose and duration, we proceeded to treat MV4-11 (n=12), Molm13 (n=9), primary AML blasts (n=10) and healthy PBMC (n=3) with VPA or PBS at a dose of 1 mM for 24 h and evaluated NKG2D-ligand expression relative to isotype control (Figure 7B).